# US 2017/0283440 A1 · Carm1 inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283440 A1
- Document ID: US20170283440A1
- Status: Published application
- Kind: A1
- Application number: 15/511,507
- Filed: 2015-09-17
- Published: 2017-10-05
- Earliest claimed: 2014-09-17
- Assignees: Epizyme, Inc.
- Applicants: Epizyme, Inc.
- Inventors: Richard Chesworth; Oscar Miguel Moradei; Gideon Shapiro; Kenneth W. Duncan; Lorna Helen Mitchell; Lei Jin; Robert E. Babine
- Web page: https://patentgrep.com/patent/US20170283440A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of the 6,5-bicyclic heteroaryl ring system, and wherein the 6-membered ring is further substituted with a group of formula -L1-R3, wherein L1 and R3 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
X is —O—, —S—, or —CH2—;
R1 is hydrogen or optionally substituted C1-4 aliphatic;
each of R2a, R2b, R2c, and R2d is independently hydrogen, halogen, —CN, —NO2, —C(═O)RA2, —C(═O)ORA2, —C(═O)N(RA2)2, —ORA2, —SRA2, —N(RA2)2, —S(═O)RA2, —S(═O)2RA2, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, wherein each instance of RA2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two RA2 groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;
Ring HET is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of the 6,5-bicyclic heteroaryl ring system, and wherein the 6-membered ring is further substituted with a group of formula-L1-R3;
L1 is a bond, —O—, —N(RL)—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(RL)—, —C(O)N(RL)N(RL)—, —OC(O)—, —OC(O)N(RL)—, —NRLC(O)—, —NRLC(O)N(RL)—, —NRLC(O)N(RL)N(RL)—, —NRLC(O)O—, —SC(O)—, —C(═NRL)—, —C(═NNRL)—, —C(═NORL)—, —C(═NRL)N(RL)—, —NRLC(═NRL)—, —C(S)—, —C(S)N(RL)—, —NRLC(S)—, —S(O)—, —OS(O)2—, —S(O)2O—, —SO2—, —N(RL)SO2—, —SO2N(RL)—, —N(RL)SO2N(RL)—, or an optionally substituted C1-10 saturated or unsaturated hydrocarbon chain, wherein one or more moieties selected from the group consisting of —O—, —N(RL)—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(RL)—, —C(O)N(RL)N(RL)—, —OC(O)—, —OC(O)N(RL)—, —NRLC(O)—, —NRLC(O)N(RL)—, —NRLC(O)N(RL)N(RL)—, —NRLC(O)O—, —SC(O)—, —C(═NRL)—, —C(═NNRL)—, —C(═NORL)—, —C(═NRL)N(RL)—, —NRLC(═NRL)—, —C(S)—, —C(S)N(RL)—, —NRLC(S)—, —S(O)—, —OS(O)2—, —S(O)2O—, —SO2—, —N(RL)SO2—, —SO2N(RL)—, and —N(RL)SO2N(RL)— is optionally and independently present between two carbon atoms of the hydrocarbon chain, and optionally and independently present at one or both ends of the hydrocarbon chain;
each RL is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or RL and R3 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring; and
R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, provided when R3 is hydrogen, then L1 is not a bond.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is of Formula (I-a):
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is of Formula (I-b):
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein X is —O—.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein X is —S—.

### Claim 6 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein X is —CH2—.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein the Ring HET is of the formula:
wherein:
G1 is C—R7 or N;
G2 is C—R8 or N;
G3 and G7 are each independently C or N;
G4 is C—R4, N, or N—R4N;
G5 is C—R5, N, or N—RN;
G6 is C—R6, N, or N—R6N;
provided at least two and not more than five instances of G1, G2, G3, G4, G5, G6, and G7 is nitrogen;
each instance of R4N, R5N, and R6N independently hydrogen, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)2, —S(═O)R′, —S(═O)2R′, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
each instance of R4, R5, R6, and R7 is independently hydrogen, halo, —CN, —NO2, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)2, —N(R′)2, —OR′, —SR′, —S(═O)R′, —S(═O)2R′, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each instance of R′ is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R′ groups attached to the same nitrogen are joined to form an optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein Ring HET is selected from the group consisting of:

### Claim 9 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 10 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 11 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 12 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 13 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 14 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 15 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 16 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 17 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 18 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 19 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 20 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 21 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 22 (depends on 8)

The compound of claim 8, wherein Ring HET is:

### Claim 23 (depends on 7, 8)

The compound of claim 7 or 8, at least one instance of R4N, R5N, and R6N is optionally substituted C3carbocyclyl or optionally substituted C1-4alkyl.

### Claim 24 (depends on 7, 8)

The compound of claim 7 or 8, at least one instance of R4, R5, R6, and R7 is hydrogen, optionally substituted C1-4-alkyl, optionally substituted C3carbocyclyl, —CN, —C(═O)R′, —C(═O)OR′, or —C(═O)N(R′)2.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 1-24, wherein L1 is a bond, —N(RL)—, —NRLC(O)O—, —NRLC(O)N(RL)—, —N(RL)—, —N(RL)SO2N(RL)—, —NRL—(CH2)x—C(O)O—, —NRL—(CH2)x—O—, —NRLC(O)N(RL)—, —NRL—(CH2)x—, —(CH2)x—NRL—NRL—, —NRLC(O)O(CH2)x—, —NRLC(O)NRL(CH2)x—, or —NRL(CH2)xNRLC(O)—.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-25, wherein R3 is an optionally substituted monocyclic or bicyclic heterocyclyl, or an optionally substituted monocyclic or bicyclic heteroaryl.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, wherein R3 is selected from the group consisting of:
wherein:
each instance of independently represents a single or double bond;
n is 0, 1, 2, or 3;
each instance of R3A is independently hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl, sulfonyl, sulfinyl, —CN, —NO2, halogen, optionally substituted alkyl, or two R3A groups are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring, or R3A and R3B groups are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring; and
R3B is hydrogen, optionally substituted alkyl, or a nitrogen protecting group.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound of any one of claims 1-27, wherein R1 is hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one claims 1-28, wherein each of R2a, R2c, and R2d is hydrogen.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one claims 1-29, wherein R2b is —F, —Cl, —Br, —I, —CN, optionally substituted C1-4 alkyl, optionally substituted C3-5 carbocyclyl, or —ORA2, wherein RA2 is optionally substituted C1-4 alkyl, or optionally substituted C3-5 carbocyclyl.

### Claim 31 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of compounds depicted in Tables 8 or 9, or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A pharmaceutical composition comprising a compound of any one of claims 1-31 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A kit or packaged pharmaceutical comprising a compound of any one of claims 1-31 or a pharmaceutically acceptable salt thereof, and instructions for use thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method of treating a CARM1-mediated disorder, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 32.

### Claim 35 (depends on 34)

The method of claim 34, wherein the disorder is a proliferative disorder.

### Claim 36 (depends on 35)

The method of claim 35, wherein the disorder is cancer.

### Claim 37 (depends on 36)

The method of claim 36, wherein the cancer is associated with E2F1 upregulation.

### Claim 38 (depends on 36, 37)

The method of claim 36 or 37, wherein the cancer is associated with aberrant CARM1 activity.

### Claim 39 (depends on 36, 37, 38)

The method of any one of claims 36-38, wherein the cancer is breast cancer, prostate cancer, or colorectal cancer.

### Claim 40 (depends on 36, 37, 38)

The method of any one of claims 36-38, wherein the cancer is ERα-dependent breast cancer.

### Claim 41 (depends on 36, 37, 38)

The method of any one of claims 36-38, wherein the cancer is castration-resistant prostate cancer.

### Claim 42 (depends on 36, 37, 38)

The method of any one of claims 36-38, wherein the cancer is colorectal cancer associated with dysregulated WNT/β-catenin signaling.

### Claim 43 (depends on 34)

The method of claim 34, wherein the disorder is a metabolic disorder.
